The findings come as welcome news as NSW lockdowns continue – but future cancer treatment patterns will depend on how current infection rates develop.
A low haemoglobin count, older age and high BMI are possible risk factors for developing nerve damage after cancer treatment, a UNSW-led study has found.
More than 15 million people each year will need chemotherapy by 2040, a landmark study published today by a team of Australian researchers has shown.
News reports that 70% of women with breast cancer don't need chemotherapy need to be heeded with caution: it's a very specific (but substantial) subtype that was studied.
Thousands of Australian cancer survivors experience chemotherapy-induced peripheral neuropathy (CIPN), but little is known about its impact on a national level.
Understanding how chemotherapy-induced nerve damage impacts on the quality of life of Australia’s cancer survivors is the goal of a new survey launched by UNSW.
The chances of a woman surviving ovarian cancer and her quality of life during treatment could be significantly improved, with an international trial about to get underway in Sydney.
In a world-first, UNSW researchers have developed a nanoparticle that could improve the effectiveness of chemotherapy for neuroblastoma by a factor of five.
UNSW medical students have donated up to $200,000 worth of equipment to hospitals in developing countries, where even the most basic tests are sometimes unavailable.